The collaboration will facilitate a clinical trial through Cerner’s Learning Health Network to aid in advancing the early detection of cancer.
The companies will leverage the research-activated network of health systems, real-world data (RWD) and Freenome’s multiomics technology to expedite early cancer detection.
This trial will be one of the first cancer screening studies offered to the Learning Health Network (LHN) of Cerner.
LHN is a group of over 85 diverse health systems in the US that collaborate to aid in advancing research and boosting equitable access to trials by offering de-identified data.
Trial participation will aid members of LHN to deliver innovative cancer prevention testing to the communities they serve irrespective of their size or location.
Freenome, Cerner and Elligo will partner to leverage RWD to carry out the Sanderson Study, an upcoming trial for detecting various cancer types which is IRB approved and utilises new multiomics technology.
A healthcare-enabling research organisation, Elligo Health Research will partner with LHN members to expedite the activation of sites and enrol a significant number of diverse patients rapidly compared to standard recruitment models.
The partnership, which covers the US, will allow the participation of diverse patients from various demographics, socio-economic factors and all community sizes.
Multiomics platform of Freenome merges tumour and non-tumour signals using machine learning to identify cancer in the initial, most treatable stages with the help of a standard blood sample.
Cerner Enviza vice-president Christy Dueck said: “The clinical research Cerner will enable has the potential to advance early cancer detection so patients can seek timely treatment and improve their chances of survival.
“Data and technology have the power to help clinicians and researchers expand therapeutic knowledge and accelerate their development and delivery, which can improve people’s lives around the world.”